MX2010002766A - 3-metil-2-((2s)-2-(4-(3-metil-l, 2, 4-oxadiazol-5-il-) fenil) morfolino) -6- (pirimidin-4-il) pirimidin-4 (3h) -ona como inhibidor de tau proteina cinasa. - Google Patents

3-metil-2-((2s)-2-(4-(3-metil-l, 2, 4-oxadiazol-5-il-) fenil) morfolino) -6- (pirimidin-4-il) pirimidin-4 (3h) -ona como inhibidor de tau proteina cinasa.

Info

Publication number
MX2010002766A
MX2010002766A MX2010002766A MX2010002766A MX2010002766A MX 2010002766 A MX2010002766 A MX 2010002766A MX 2010002766 A MX2010002766 A MX 2010002766A MX 2010002766 A MX2010002766 A MX 2010002766A MX 2010002766 A MX2010002766 A MX 2010002766A
Authority
MX
Mexico
Prior art keywords
pyrimidin
methyl
protein kinase
tau protein
0xadiaz0l
Prior art date
Application number
MX2010002766A
Other languages
English (en)
Inventor
Kazutoshi Watanabe
Daiki Sakai
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2010002766A publication Critical patent/MX2010002766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable de él: (ver fórmula (I)) que se usa para el tratamiento preventivo y/o terapéutico de una enfermedad provocada por la actividad anormal de la tau proteína cinasa 1 tal como enfermedades neurodegenerativas (por ejemplo, la enfermedad de Alzheimer).
MX2010002766A 2007-09-14 2008-09-12 3-metil-2-((2s)-2-(4-(3-metil-l, 2, 4-oxadiazol-5-il-) fenil) morfolino) -6- (pirimidin-4-il) pirimidin-4 (3h) -ona como inhibidor de tau proteina cinasa. MX2010002766A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007269484 2007-09-14
JP2007275714 2007-09-25
PCT/JP2008/066929 WO2009035159A1 (en) 2007-09-14 2008-09-12 3-methyl-2- ( (2s) -2- (4- (3-methyl-l, 2, 4-0xadiaz0l-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2010002766A true MX2010002766A (es) 2010-05-19

Family

ID=40085496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002766A MX2010002766A (es) 2007-09-14 2008-09-12 3-metil-2-((2s)-2-(4-(3-metil-l, 2, 4-oxadiazol-5-il-) fenil) morfolino) -6- (pirimidin-4-il) pirimidin-4 (3h) -ona como inhibidor de tau proteina cinasa.

Country Status (14)

Country Link
US (1) US8288383B2 (es)
EP (1) EP2197877B1 (es)
JP (1) JP5449147B2 (es)
KR (1) KR20100074183A (es)
CN (1) CN101842371A (es)
AR (1) AR068438A1 (es)
AU (1) AU2008297814A1 (es)
BR (1) BRPI0816708A2 (es)
CA (1) CA2698818A1 (es)
EA (1) EA201070366A1 (es)
MX (1) MX2010002766A (es)
TW (1) TW200927133A (es)
WO (1) WO2009035159A1 (es)
ZA (1) ZA201002214B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
JP5442852B2 (ja) * 2009-08-13 2014-03-12 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
WO2012007426A1 (en) 2010-07-13 2012-01-19 Basf Se Azoline substituted isoxazoline benzamide compounds for combating animal pests
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2554843T3 (es) 2012-01-12 2015-12-23 F. Hoffmann-La Roche Ag Derivados heterocíclicos como receptores asociados de trazas de amina (TAARs)
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
CN113831296B (zh) * 2021-07-27 2023-07-21 北京理工大学 1-苯基-3-(4-(嘧啶-5-基氨基)苯基)丙-2-烯-1-酮类化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI265164B (en) * 2001-09-21 2006-11-01 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
PL368816A1 (en) * 2001-09-21 2005-04-04 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
KR20100074183A (ko) 2010-07-01
CN101842371A (zh) 2010-09-22
JP2010538970A (ja) 2010-12-16
EA201070366A1 (ru) 2010-08-30
US8288383B2 (en) 2012-10-16
JP5449147B2 (ja) 2014-03-19
BRPI0816708A2 (pt) 2015-03-17
TW200927133A (en) 2009-07-01
US20110003988A1 (en) 2011-01-06
WO2009035159A1 (en) 2009-03-19
EP2197877B1 (en) 2013-05-15
AU2008297814A1 (en) 2009-03-19
AR068438A1 (es) 2009-11-18
CA2698818A1 (en) 2009-03-19
WO2009035159A8 (en) 2010-07-29
EP2197877A1 (en) 2010-06-23
ZA201002214B (en) 2011-06-29

Similar Documents

Publication Publication Date Title
MX2010002766A (es) 3-metil-2-((2s)-2-(4-(3-metil-l, 2, 4-oxadiazol-5-il-) fenil) morfolino) -6- (pirimidin-4-il) pirimidin-4 (3h) -ona como inhibidor de tau proteina cinasa.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MY162157A (en) Substituted indole mcl-1 inhibitors
MX2009000333A (es) Pirrilopirimidinas para composiciones farmaceuticas.
EA200901373A1 (ru) Аминогетероциклические соединения
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
TW200626573A (en) Pyrimidone compound
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
TN2011000293A1 (en) Protein kinase inhibitors
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
MX2012002480A (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
NZ594332A (en) Compounds for the prevention and treatment of cardiovascular disease
MX346186B (es) Inhibidores de proteina cinasas.
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
TW200801018A (en) 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
ATE523498T1 (de) Hiv-inhibierende 2-(4- cyanophenylamino)pyrimidinderivate
MX2010002765A (es) Derivado de 6-pirimidinil-pirimid-4-ona.
DE602007001952D1 (de) 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal